Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 4, 2017, Pages

  Sandercock, Peter Ag ^a   Leong, Tze Shin ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ACTIVITY OF DAILY LIVING ASSESSMENT; ANTICOAGULANT THERAPY; BLOOD CLOT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; DEEP VEIN THROMBOSIS; HUMAN; INTERVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ACUTE DISEASE; CHEMICALLY INDUCED; HEMORRHAGE; MORTALITY; PULMONARY EMBOLISM; STROKE; VENOUS THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; BRAIN ISCHEMIA; CAUSE OF DEATH; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARINOIDS; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VENOUS THROMBOSIS;

EID: 85017185718     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000119.pub4     Document Type: Review

References (75)

1. Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberich R, Abedinpour F, et al. A multi-centre double blind randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age and Ageing 1994;23(6):512-6. 2764210
2. Hageluken C, Egberts J, Stiekema J. A multi-centre, assessor-blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non-haemorrhagic stroke of recent onset (protocol 87038). Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands 1992. 2764211
3. Hageluken C, Egberts J. A multi-centre, assessor-blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non-haemorrhagic stroke of recent onset (protocol 85144). Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands 1992. 2764213
4. Hillbom M, Erila T, Flosbach C, Sotaniemi K, Tatlisumak T, Sarna S, et al. Enoxaparin, a low-molecular-weight heparin (LWMH) may be superior to standard heparin in the prevention of deep-vein thrombosis (DVT) in stroke patients. European Journal of Neurology 1998;5(Suppl 3):S110. 2764215
5. Hillbom M, Erila T, Flosbach CW, Sotaniemi K, Sarna S, Kaste M. Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke. Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14-21; Washington, DC, USA. 1999. 2764216
6. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. Blood 1999;94(Suppl 1):183a. 2764217
7. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurologica Scandinavica 2002;106(2):84-92. 2764218
8. Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke 2009;40(11):3532-40. [DOI: 10.1161/STROKEAHA.109.555003]5325237
9. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007;369(9570):1347-55. 2764220
10. Diener H-C, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J, et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin. Results of the PROTECT Trial. Stroke 2006;37(1):139-44. 2764222
11. Hossman V, Loettgen J, Auel H, Bewermeyer H, Heiss WD. Prophylaxis of deep vein thrombosis in acute stroke. A prospective, randomised double-blind study. Haemostasis 1986;16(Suppl 5):54. 2764224
12. Stiekema JCJ, Egberts JFM, Voerman J. An open, randomised, pilot multi-centre study of Org 10172 versus heparin administered for the purpose of deep vein thrombosis prophylaxis in patients with a non-haemorrhagic stroke of recent onset. Organon International B.V. (Internal report SDGRR No. 2310). Oss, The Netherlands 1988. 2764225
13. Woessner R, Grauer M, Bianchi O, Mueller M, Moersdorf S, Berlit P, et al. Treatment with anticoagulants in cerebral events (TRACE). Thrombosis and Haemostasis 2004;91(4):690-3. 2764227
14. Magnani HN, Egberts JFM. A preliminary report of a multi-centre, assessor-blind, randomised, comparative safety and efficacy study of Org 10172 versus low dose heparin, administered subcutaneously twice daily for the prophylaxis of deep vein thrombosis in patients with acute thrombotic stroke (protocol 004-010). Organon International B.V (Internal report SDGRR No.3172). Oss, the Netherlands 1992. 2764229
15. Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992;22(2):92-8. 2764232
16. Turpie AGG, Levine MN, Powers PJ, Ginsberg JG, Jay RM, Klimek M, et al. A double blind randomized trial of Org 10172 low molecular weight heparinoid versus unfractionated heparin in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis 1991;65:753. 2764230
17. Turpie AGG, Levine MN, Powers PJ, Ginsberg JG, Jay RM, Klimek M, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Annals of Internal Medicine 1992;117(5):353-7. 2764231
18. Wong WJ, Lo YK, Hu HH. Comparison of subcutaneous low-molecular heparin with intravenous standard heparin in progressive ischaemic stroke. Journal of Stroke and Cerebrovascular Diseases 2000;9(Suppl 1):183-4. 2764234
19. Assadian A, Knobl P, Hubl W, Senekowitsch C, Klingler A, Pfaffelmeyer N, et al. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. Journal of Vascular Surgery 2008;47(3):537-42. 5325239
20. Dunatov S, Antoncic I, Strenja-Linic I, Tuskan-Mohar L. Low molecular weight heparin (LMWH) as an adjunct to thrombolysis for acute stroke. International Journal of Stroke 2008;3 (Suppl 1):238. 5325241
21. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thrombosis and Haemostasis 1996;76(4):529-34. 2764236
22. Egberts JFM, Sommer W. Multicentre, randomised, assessor-blind, dose-comparative study of Org 10172 (Orgaran) in the treatment of acute ischaemic stroke. Personal communication by letter 1996. 2764238
23. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine 2010;153(1):8-18. [DOI: 10.7326/0003-4819-153-1-201007060-00004]5325243
24. Feiz F, Sedghi R, Salehi A, Hatam N, Bahmei J, Borhani-Haghigi A. Study of the efficacy, safety and tolerability of low-molecular weight heparin vs unfractionated heparin as bridging therapy for patients with embolic stroke due to atrial fibrillation. Journal of Vascular and Interventional Neurology 2016;9(1):35-41. 5325245
25. Geng S, Wang Y, Liu P. Intravenous drip of urokinase combined with low molecular weight heparin in the treatment of acute cerebral infarction. Practical Journal of Medicine and Pharmacy 2004;21(7):604-6. 5325247
26. Harenberg J, Schomaker U, Floshbach CW. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk. Blood 1999;94(Suppl 10):399a. 2764240
27. Dluha J, Sivak S, Kurca E, Dusenka R, Kalmarova K, Turcanova-Koprusakova M, et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers 2016;160(4):543-8. 5325249
28. NCT01862978 . Safety and efficacy of heparin and nadroparin in the acute phase of ischaemic stroke (Heparinas). clinicaltrials.gov/ct2/show/NCT01862978 (first received 20 May 2013). 5325250
29. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thrombosis Research 1990;59(3):639-50. 2764242
30. Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL, et al. Heparin study in internal medicine (HESIM): design and preliminary results. Thrombosis Research 1992;68(1):33-43. 2764243
31. IRCT201109067495N1 . Clinical trial on enoxaparine and aspirin effects on mobility problems of non-hemorrhagic stroke patients. en.search.irct.ir/view/7105 (first received 10 December 2011). 5325252
32. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine 2013;368(6):513-52. [DOI: 10.1056/NEJMoa1111096]5325254
33. McCarthy S, McWalter R, Durkin CJ, Hallawi AH. Org 10172 for the prophylaxis of deep venous thrombosis in the legs. A protocol to establish the efficacy and safety of once or twice daily subcutaneous Org 10172 injections vs placebo in 3 groups of 60 non-haemorrhagic stroke victims. Unpublished protocol. 2764245
34. Mikulik R, Dufek M, Goldemund D, Reif M. A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke. European Journal of Neurology 2006;13(10):1106-11. 5325256
35. Crepin-Leblond T, Moulin T, Ziegler F, Bataillard M, Chopard L, Chavot D, et al. A randomised trial of heparin therapy in acute ischemic stroke: first results. Cerebrovascular Diseases 1994;4:259. 2764247
36. NCT01763606 . Enoxaparin versus aspirin in patients with cancer and stroke. clinicaltrials.gov/ct2/show/NCT01763606 (first received 20 December 2012). 5325258
37. Necioglu Orken D, Kenangil G, Ozkurt H, Guner C, Gundogdu L, Basak M, et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. The Neurologist 2009;15(6):329-31. 5325260
38. Nikc Evic LD, Savic MB, Plavsic AT, Hrkovic MK. Applying of LMWH (clexane) and results of early rehabilitation in patients after ischemic stroke. International Journal of Stroke 2006;1(Suppl 1):153. 2764249
39. Szirmai I, Fendler K, Kollár L, Romhányi M. Clinical experience with heparinoid sodium pentosan polysulphate (SP54) in treatment of cerebral ischaemia. Folia Haematologia (Leipzig) 1986;113(1-2):278-88. 2764251
40. Tan A. The application research on the treatment of acute ischemic stroke by using low molecular weight heparins and small dose of heparins. Journal of Medical Theory and Practice 2002;15(11):1246-7. 5325262
41. Trencev R, Stojanov M, Petrovska-Cvetkovska D, Georgievska A, Baneva N, Radulovic-Bekarovska S. Low-molecular-weight heparin vs aspirin in treatment of cardioembolic stroke. International Journal of Stroke 2008; Vol. 3, issue Suppl 1:315-6. 5325264
42. Trouillas P, Derex L, Philippeau F, Cakmak S, Nighoghossian N, Zeng L. RT-PA and heparin in the LYON RT-PA protocol: beneficial effect of intravenous heparin on outcome and intracerebral bleeding at specific times of initiation. Cerebravascular Diseases 2008;25(Suppl 2):42-3. 5325266
43. Wang ZY, Wang LC, Chen C, Gen JY, Gao YS. A controlled study on the treatment of acute progressive cerebral infarction by continuous anticoagulation with small doses of heparin. Chinese Critical Care Medicine 2012;24(5):290-3. 5325268
44. Xing ZW, Shi YD. Clinical observation of combined clopidogrel and low molecular heparin in progressive ischemic stroke. Chinese Journal of Contemporary Neurology and Neurosurgery 2006;6(1):44-6. 5325270
45. Aventis Pharma. An open-label, randomised, parallel-group, multi-centre study to evaluate the efficacy and safety of enoxaparin versus unfractionated heparin in the prevention of venous thromboembolism in patients following acute ischaemic stroke. Unpublished. 2764253
46. Young WD, Smythe LG. Low-molecular-weight heparin (enoxaparin) in anticoagulation transition to oral warfarin in ischaemic cerebral vascular accident (CVA) or transient ischaemic attack (TIA) patients. ASHP Midyear Clinical Meeting. 2001; Vol. 36:496E. 2764255
47. Amin AN, Lin J, Thompson S, Wiederkehr D. Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology 2013;13:17. [DOI: 10.1186/1471-2377-13-17]
48. Bath P, Iddenden R, Bath F. Low-molecular weight heparins and heparinoids in acute ischemic stroke. Stroke 2000;31(7):1770-8.
49. Caplan LR. Caplan's stroke: a clinical approach. Basic Pathology, Anatomy, and Pathophysiology of Stroke. 4th Edition. Philadelphia: Saunders Elsevier, 2009:22.
50. Cella G, Scattolo N, Luzzato G, Stevanato F, Vio C, Girolami A. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. Journal of Medicine 1986;17(5-6):331-46.
51. Choay J. Structure and activity of heparin and its fragments: an overview. Seminars in Thrombosis and Hemostasis 1989;15(4):359-64.
52. Chung JW, Kim BJ, Han MK, Ko Y, Lee S, Kang K, et al. Impact of guidelines on clinical practice: intravenous heparin use for acute ischemic stroke. Stroke 2016;47(6):1577-83. [DOI: 10.1161/STROKEAHA.116.012639]
53. Dennis M, Sandercock P, Graham C, Forbes J, Clots Trials Collaboration. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technology Assessment 2015;19(76):1-90. [DOI: 10.3310/hta19760]
54. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Archives of Internal Medicine 1991;151(2):333-7.
55. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S-43S.
56. Gordon DL, Linhardt R, Adams HP. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clinical Neuropharmacology 1990;13(6):522-43.
57. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2]
58. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
59. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:52s.
60. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569-81.
61. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine 2011;155(9):602-15.
62. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. [DOI: 10.1016/S0140-6736(12)61728-0]
63. Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22(2):58-65.
64. Odgaard-Jensen J, Vist Gunn E, Timmer A, Kunz R, Akl EA, Schnemann H, et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.MR000012.pub3]
65. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
66. Sandercock PAG, van den Belt A, Lindley R, Slattery J. Antithrombotic therapy in acute stroke: an overview of the randomised trials. Journal of Neurology, Neurosurgery & Psychiatry 1993;56(1):17-25.
67. Sandercock P, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD000029.pub3]
68. Sandercock P, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD000024]
69. Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a meta-analysis. Chest 2008;133(1):149-55.
70. Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (Danaparoid) and outcome after acute ischemic stroke. JAMA 1998;279(16):1265-72.
71. Warlow C, Dennis M, Van Gijn J, Sandercock P, Bamford J, Rothwell P, Rinkel G, Sudlow C, Wardlaw J. Stroke: A practical Guide to Management . 3. Oxford: Blackwell Science 2008, 2008.
72. Weitz JI. Low-molecular-weight heparins. New England Journal of Medicine 1997;337(10):688.
73. Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000119]
74. Sandercock P, Counsell C, Stobbs SL. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD000119.pub2]
75. Sandercock PAG, Counsell C, Tseng M-C. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD000119.pub3]